Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis
- PMID: 38782564
- DOI: 10.1136/gutjnl-2024-332491
Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis
Abstract
Objective: Epidemiological studies have reported an association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease (MASLD). However, the magnitude of the risk and whether this risk changes with the severity of MASLD remains uncertain. We performed a meta-analysis of observational studies to quantify the magnitude of the association between primary hypothyroidism and the risk of MASLD.
Design: We systematically searched PubMed, Scopus and Web of Science from database inception to 31 January 2024, using predefined keywords to identify observational studies in which MASLD was diagnosed by liver biopsy, imaging or International Classification of Diseases codes. A meta-analysis was performed using random-effects modelling.
Results: We identified 24 cross-sectional and 4 longitudinal studies with aggregate data on ~76.5 million individuals. Primary hypothyroidism (defined as levothyroxine replacement treatment, subclinical hypothyroidism or overt hypothyroidism) was associated with an increased risk of prevalent MASLD (n=24 studies; random-effects OR 1.43, 95% CI 1.23 to 1.66; I2=89%). Hypothyroidism was also associated with a substantially higher risk of metabolic dysfunction-associated steatohepatitis or advanced fibrosis (n=5 studies; random-effects OR 2.84, 95% CI 2.07 to 3.90; I2=0%). Meta-analysis of data from four longitudinal studies showed that there was a marginally non-significant association between hypothyroidism and risk of developing MASLD over a median 4.5-year follow-up (random-effects HR 1.39, 95% CI 0.98 to 1.97; I2=85%). Sensitivity analyses did not modify these findings. The funnel plot did not reveal any significant publication bias.
Conclusion: This large and updated meta-analysis provides evidence that primary hypothyroidism is significantly associated with both an increased presence of and histological severity of MASLD.
Keywords: meta-analysis; nonalcoholic steatohepatitis.
© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
Exploring the nexus between hypothyroidism and metabolic dysfunction-associated steatotic liver disease: a UK biobank cohort study.Sci Rep. 2025 Feb 25;15(1):6692. doi: 10.1038/s41598-025-91221-7. Sci Rep. 2025. PMID: 40000892 Free PMC article.
-
Association between MASLD and increased risk of serious bacterial infections requiring hospital admission: A meta-analysis.Liver Int. 2025 Apr;45(4):e16101. doi: 10.1111/liv.16101. Epub 2024 Sep 11. Liver Int. 2025. PMID: 39258758 Free PMC article.
-
Relationship between Helicobacter pylori infection and risk of metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis.Liver Int. 2024 Jul;44(7):1513-1525. doi: 10.1111/liv.15925. Epub 2024 Apr 3. Liver Int. 2024. PMID: 38567962
-
Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.Thyroid. 2018 Oct;28(10):1270-1284. doi: 10.1089/thy.2018.0257. Epub 2018 Aug 30. Thyroid. 2018. PMID: 30084737
-
Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis.Gut. 2022 Jan;71(1):156-162. doi: 10.1136/gutjnl-2020-323082. Epub 2020 Dec 10. Gut. 2022. PMID: 33303564
Cited by
-
Resmetirom and thyroid hormone receptor-targeted treatment for metabolic dysfunction-associated steatotic liver disease (MASLD).Portal Hypertens Cirrhosis. 2025 Mar;4(1):66-78. doi: 10.1002/poh2.100. Epub 2025 Jan 22. Portal Hypertens Cirrhosis. 2025. PMID: 40777891
-
Triglyceride-glucose-waist circumference index: A powerful tool for metabolic dysfunction-associated steatotic liver disease.World J Hepatol. 2025 Jul 27;17(7):107668. doi: 10.4254/wjh.v17.i7.107668. World J Hepatol. 2025. PMID: 40747214 Free PMC article. Review.
-
Exploring the nexus between hypothyroidism and metabolic dysfunction-associated steatotic liver disease: a UK biobank cohort study.Sci Rep. 2025 Feb 25;15(1):6692. doi: 10.1038/s41598-025-91221-7. Sci Rep. 2025. PMID: 40000892 Free PMC article.
-
Metabolic Syndrome and Liver Disease: Re-Appraisal of Screening, Diagnosis, and Treatment Through the Paradigm Shift from NAFLD to MASLD.J Clin Med. 2025 Apr 16;14(8):2750. doi: 10.3390/jcm14082750. J Clin Med. 2025. PMID: 40283580 Free PMC article. Review.
-
Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease.Medicina (Kaunas). 2024 Dec 30;61(1):38. doi: 10.3390/medicina61010038. Medicina (Kaunas). 2024. PMID: 39859020 Free PMC article. Review.